Recombinant Human CD178/FASLG/TNFSF6, N-His

Description of Recombinant Human CD178/FASLG/TNFSF6, N-His

Introduction to Recombinant Human CD178/FASLG/TNFSF6, N-His

Recombinant Human CD178/FASLG/TNFSF6, N-His is a protein that has shown great potential as a drug target for cancer therapy. This protein is a member of the tumor necrosis factor (TNF) superfamily and plays a crucial role in the regulation of apoptosis, or programmed cell death. It is commonly referred to as CD178 or FAS ligand (FASLG) and is encoded by the TNFSF6 gene.

Structure of Recombinant Human CD178/FASLG/TNFSF6, N-His

The recombinant form of CD178/FASLG/TNFSF6, N-His is a 40 kDa protein consisting of 281 amino acids. It is a type II transmembrane protein, meaning it has a hydrophobic region that anchors it to the cell membrane. The extracellular region of the protein contains a TNF homology domain, which is responsible for binding to its receptor, FAS. The intracellular region contains a death domain, which is essential for initiating the apoptotic signaling pathway.

Activity of this protein

The main function of CD178/FASLG/TNFSF6 is to induce apoptosis in target cells through binding to its receptor, FAS. This binding triggers a cascade of events that ultimately leads to cell death. This process is important for maintaining tissue homeostasis and eliminating damaged or infected cells. However, dysregulation of CD178/FASLG/TNFSF6 has been linked to various diseases, including cancer.

In addition to its role in apoptosis, CD178/FASLG/TNFSF6 has also been shown to have immunomodulatory effects. It can stimulate the production of cytokines and chemokines, which are important for regulating the immune response. This activity has been implicated in the development of autoimmune diseases and inflammatory disorders.

Application of Recombinant Human CD178/FASLG/TNFSF6, N-His

The potential of CD178/FASLG/TNFSF6 as a drug target for cancer therapy has been extensively studied. It has been found to be overexpressed in various types of cancer, including breast, lung, and colon cancer. This overexpression has been associated with increased resistance to chemotherapy and poor patient outcomes.

One promising application of recombinant CD178/FASLG/TNFSF6 is in immunotherapy. By targeting this protein, researchers aim to activate the immune system to specifically kill cancer cells. This approach has shown promising results in preclinical studies and is currently being evaluated in clinical trials for various types of cancer.

Another potential application is in combination therapy with existing cancer treatments. CD178/FASLG/TNFSF6 has been shown to sensitize cancer cells to chemotherapy and radiation therapy, making them more susceptible to treatment. This could potentially improve the efficacy of these treatments and reduce the risk of resistance.

Conclusion

In conclusion, Recombinant Human CD178/FASLG/TNFSF6, N-His is a promising drug target for cancer therapy. Its role in regulating apoptosis and its immunomodulatory effects make it an attractive target for the development of new treatments. Further research and clinical trials are needed to fully understand the potential of this protein in cancer therapy, but the current evidence suggests that it could be a valuable addition to the arsenal of anti-cancer therapies.